PriceTargets.com logo

Co-Diagnostics - CODX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $1.50
  • Forecasted Upside: 105.48%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.73 As of 12/20/2024 06:16 PM ET
▲ +0.0048 (0.66%)

This chart shows the closing price for CODX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Co-Diagnostics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CODX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CODX

Analyst Price Target is $1.50
▲ +105.48% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Co-Diagnostics in the last 3 months. The average price target is $1.50, with a high forecast of $1.50 and a low forecast of $1.50. The average price target represents a 105.48% upside from the last price of $0.73.

This chart shows the closing price for CODX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in Co-Diagnostics. This rating has held steady since November 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/11/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$1.50 ➝ $1.50
8/12/2024HC WainwrightLower TargetNeutral ➝ Neutral$2.00 ➝ $1.50
6/17/2024HC WainwrightReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00
5/13/2024HC WainwrightLower TargetNeutral ➝ Neutral$2.50 ➝ $2.00
3/15/2024HC WainwrightLower TargetNeutral ➝ Neutral$3.00 ➝ $2.50
12/29/2023HC WainwrightReiterated RatingNeutral ➝ Neutral$3.00
11/13/2023HC WainwrightBoost TargetNeutral ➝ Neutral$2.00 ➝ $3.00
8/14/2023HC WainwrightLower TargetNeutral ➝ Neutral$3.00 ➝ $2.00
3/20/2023HC WainwrightDowngradeBuy ➝ Neutral
2/23/2023HC WainwrightReiterated RatingBuy$6.00
12/1/2022Litchfield Hills ResearchReiterated RatingBuy
11/14/2022HC WainwrightLower TargetBuy$9.00 ➝ $6.00
8/15/2022HC WainwrightLower TargetBuy$12.00 ➝ $9.00
8/12/2022SidotiDowngradeBuy ➝ Neutral$5.00
5/27/2022HC WainwrightReiterated RatingBuy$12.00
5/16/2022HC WainwrightLower TargetNA$15.00 ➝ $12.00
3/25/2022HC WainwrightReiterated RatingBuy$15.00
12/29/2021SidotiInitiated CoverageBuy$14.00
12/23/2021HC WainwrightReiterated RatingBuy$15.00
12/8/2021HC WainwrightReiterated RatingBuy$15.00
11/30/2021HC WainwrightReiterated RatingBuy$15.00
11/15/2021Litchfield Hills ResearchReiterated RatingBuy
11/12/2021Maxim GroupReiterated RatingHold
11/12/2021HC WainwrightLower TargetBuy$16.00 ➝ $15.00
10/7/2021HC WainwrightReiterated RatingBuy$16.00
9/17/2021HC WainwrightReiterated RatingBuy$16.00
3/29/2021Maxim GroupDowngradeBuy ➝ Hold
3/26/2021HC WainwrightLower TargetBuy$30.00 ➝ $16.00
12/15/2020HC WainwrightBoost TargetBuy$29.00 ➝ $30.00
11/17/2020Maxim GroupLower TargetPositive ➝ Buy$30.00 ➝ $20.00
11/17/2020HC WainwrightLower TargetBuy$33.00 ➝ $29.00
8/31/2020HC WainwrightReiterated RatingBuy$33.00
8/14/2020Maxim GroupInitiated CoverageBuy$30.00
8/14/2020HC WainwrightLower TargetBuy$35.00 ➝ $33.00
8/3/2020HC WainwrightReiterated RatingBuy$35.00
7/13/2020HC WainwrightReiterated RatingBuy$35.00
5/27/2020Maxim GroupReiterated RatingBuy$30.00
5/20/2020Maxim GroupUpgradeHold ➝ Buy
4/17/2020HC WainwrightReiterated RatingBuy
3/23/2020HC WainwrightReiterated RatingBuy
3/20/2020Maxim GroupReiterated RatingHold
3/3/2020Maxim GroupDowngradeBuy ➝ Hold
2/24/2020HC WainwrightBoost TargetBuy$2.00 ➝ $4.00
1/3/2020HC WainwrightReiterated RatingBuy$2.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Co-Diagnostics logo
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Read More

Today's Range

Now: $0.73
Low: $0.72
High: $0.77

50 Day Range

MA: $1.06
Low: $0.73
High: $1.32

52 Week Range

Now: $0.73
Low: $0.70
High: $2.23

Volume

168,731 shs

Average Volume

141,359 shs

Market Capitalization

$23.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Co-Diagnostics?

The following Wall Street analysts have issued reports on Co-Diagnostics in the last year: HC Wainwright.
View the latest analyst ratings for CODX.

What is the current price target for Co-Diagnostics?

0 Wall Street analysts have set twelve-month price targets for Co-Diagnostics in the last year. Their average twelve-month price target is $1.50, suggesting a possible upside of 105.5%. HC Wainwright has the highest price target set, predicting CODX will reach $1.50 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $1.50 for Co-Diagnostics in the next year.
View the latest price targets for CODX.

What is the current consensus analyst rating for Co-Diagnostics?

Co-Diagnostics currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CODX, but not buy more shares or sell existing shares.
View the latest ratings for CODX.

What other companies compete with Co-Diagnostics?

Other companies that are similar to Co-Diagnostics include FONAR, Monogram Orthopaedics, electroCore, LENSAR and Edap Tms. Learn More about companies similar to Co-Diagnostics.

How do I contact Co-Diagnostics' investor relations team?

Co-Diagnostics' physical mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84124. The company's listed phone number is (801) 438-1036 and its investor relations email address is [email protected]. The official website for Co-Diagnostics is www.codiagnostics.com. Learn More about contacing Co-Diagnostics investor relations.